Study at a glance
Why did hospital staff sometimes order the wrong vitamin D blood test?
Researchers asked why hospital staff sometimes ordered the wrong vitamin D test. The usual test measures 25-hydroxyvitamin D to assess vitamin D levels. A separate test measures 1,25-dihydroxyvitamin D, the active hormone. This second test has specialist uses, but it does not answer the same question.
How did researchers study hospital vitamin D test orders?
Two studies examined hospital test orders after computer ordering systems were introduced. The page also uses research reviews to explain the tests and their limits. The hospital studies examined ordering patterns, rather than whether testing improved patients’ health.
Did clearer names and ordering systems reduce use of the wrong vitamin D test?
One medical centre found 43 sets of electronic ordering options that included the active-hormone test when staff intended routine vitamin D checks. Correcting the options, adding a warning and educating staff reduced these orders. At two other hospitals, orders rose after computer ordering began and fell after test names became clearer.
What can clearer vitamin D test names help hospital staff do?
Clear test names can help staff choose the test that matches their question. A normal active-hormone result can occur alongside low 25-hydroxyvitamin D. Laboratory methods and changes within the body can affect results even when the right test is chosen. The studies do not show that every active-hormone test is unnecessary, that everyone needs testing or that one target blood level suits everyone.
Read the full article below ↓The main vitamin D testing error is not always a bad assay result. Sometimes the wrong metabolite is ordered. 25-hydroxyvitamin D is the usual biomarker for vitamin D status, while 1,25-dihydroxyvitamin D is a tightly regulated active hormone used mainly for selected specialist questions. Real-world hospital studies show that these similarly named tests are genuinely confused.
What question did this evidence investigate?
The evidence asks what happens when 1,25(OH)₂D is used for the wrong purpose, why clinicians can confuse it with 25(OH)D, and what limitations remain even after the correct status biomarker has been selected.
What was studied?
Two quality-improvement studies examined ordering behaviour after electronic ordering systems were introduced. Laboratory medicine reviews were used to clarify what each metabolite measures and how assay limitations affect interpretation. Current clinical guidance supplies a separate boundary around routine screening.
What did the hospital studies find?
At one academic centre, 43 electronic order sets contained 1,25(OH)₂D when the clinical owners actually intended routine vitamin D status screening. Correcting the order sets, adding a warning and providing education reduced active-hormone orders. At two other hospitals, electronic ordering was followed by estimated monthly increases of 24.8 and 14.2 1,25(OH)₂D tests; clearer test naming was followed by decreases of 22.1 and 11.3 tests per month.
Why can the wrong biomarker mislead?
1,25(OH)₂D is regulated by the kidney, PTH, FGF23 and feedback, so it does not simply track vitamin D stores. It can remain normal when 25(OH)D is low, and it can be altered by renal or mineral disorders. That makes it inappropriate as a routine substitute for 25(OH)D status testing.
When can 1,25(OH)₂D be useful?
The active hormone has legitimate specialist roles in selected disorders of activation, receptor resistance, inappropriate extra-renal production and phosphate regulation. The correct lesson is not “never measure 1,25(OH)₂D,” but “measure it when the clinical question is about active-hormone physiology rather than ordinary vitamin D status.”
What did the independent replication add?
The second ordering study showed that the problem was not confined to one institution or one erroneous set of order templates. At two hospitals, 1,25(OH)₂D ordering rose after computerised order entry and fell after the test names were changed to make their purpose clearer. That supports a general human-factors explanation: closely related metabolite names can lead users toward the wrong clinical test unless the ordering system makes the distinction explicit.
The studies do not prove that every 1,25(OH)₂D order is inappropriate. They show that unnecessary active-hormone testing can be generated by the ordering environment, and that correcting the interface can reduce it without removing legitimate specialist access.
What are the main limitations of 25(OH)D testing?
25(OH)D is the correct status marker, but assay methods are not perfectly interchangeable. Automated methods can perform differently in some patient groups and may have difficulty with vitamin D₂-related measurements. Standardised LC-MS/MS can be preferable in selected settings. Biological variation adds another layer, discussed in Biological Noise in Vitamin D Testing.
Does this mean everyone should have 25(OH)D measured?
No. Biomarker choice and testing indication are separate questions. The 2024 Endocrine Society guideline suggests against routine 25(OH)D screening in generally healthy adults without another established indication. The fact that 25(OH)D is the appropriate status biomarker does not create a universal requirement to test.
What does this evidence not establish?
The ordering studies do not define every legitimate reason to measure 1,25(OH)₂D, and they do not show that every active-hormone order is wasteful. They show that the test can be selected mistakenly when clinicians intend ordinary status assessment. The assay reviews likewise do not make 25(OH)D unusable; they show that method-specific limitations need to be recognised, especially when the result is unexpected or the patient context is analytically difficult.
The evidence also does not supply a universal 25(OH)D target for every person. Biomarker selection, assay performance, interpretation of thresholds and the clinical indication for testing are separate questions.
Why this matters within vitamin D physiology
The safest interpretation begins with the question being asked. Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D explains the two-metabolite distinction, while Limitations of Vitamin D Blood Tests explores the wider constraints of blood testing. A laboratory number is useful only when the chosen biomarker, analytical method and physiological interpretation all align.
For the deeper evidence review, see Choosing the Correct Vitamin D Biomarker: Clinical Limitations and Misinterpretation Risks: Full Study.
Primary evidence and source details
Promoting improved utilization of laboratory testing through changes in an electronic medical record: experience at an academic medical center. Krasowski MD et al. BMC Medical Informatics and Decision Making. 2015;15:11.
Optimizing vitamin D naming conventions in computerized order entry to support high-value care. White AA et al. Journal of the American Medical Informatics Association. 2017;24:172 to 175.
Vitamin D: marker, measurand & measurement. Dirks NF, Cavalier E, Heijboer AC. Endocrine Connections. 2023;12:e220269.
Related reading
Longitudinal biomarker trajectories accompanying trichoscopic change after PRP-based regimens for alopecia: a complementary multi-marker analysis of a real-world cohort
This study aimed to provide a complementary longitudinal analysis of the same real-world treatment cohort, focusing on within-subject trichoscopic change and paired biomarker trajectories rather than on baseline response stratification.
Original paper ↗Read more →25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Full Study
Explore why 25(OH)D reflects vitamin D status while 1,25(OH)₂D is a tightly regulated active hormone, including PTH, FGF23 and renal control.
Read more →25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Study Summary
A concise evidence summary explaining how 25(OH)D and 1,25(OH)₂D differ in physiological meaning, regulation and their roles in vitamin D testing.
Read more →Choosing the Correct Vitamin D Biomarker: Clinical Limitations and Misinterpretation Risks: Full Study
Review evidence on choosing the correct vitamin D biomarker, why 25(OH)D and 1,25(OH)₂D are confused, and how inappropriate testing can mislead.
Read more →1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism
Randomized, prospective studies are necessary to elucidate whether vitamin D supplementation additionally increases serum 1,25(OH)2D and possibly enhances the adverse effects on the skeleton in patients with PHPT.
Original paper ↗Read more →1,25-Dihydroxyvitamin D to PTH(1 to 84) Ratios Strongly Predict Cardiovascular Death in Heart Failure
Here, the association of 1,25(OH)2D and PTH(1 to 84) levels was evaluated for prediction of cardiovascular death in chronic HF patients.
Original paper ↗Read more →Bioconversion of vitamin D3 to bioactive calcifediol and calcitriol as high-value compounds
Biological catalysis is an important approach for the production of high-value-added compounds, especially for products with complex structures.
Original paper ↗Read more →Calcitriol supplementation accelerates the recovery of patients with tuberculosis who have vitamin D deficiency: a randomized, single-blind, controlled clinical trial
This study aimed to evaluate whether calcitriol supplementation enhances CD4+ T cell count and prognosis in patients with tuberculosis and low 25(OH)D levels.
Original paper ↗Read more →Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Concentrations and Postoperative Infections in Cardiac Surgical Patients: The CALCITOP-Study
In 3,340 consecutive cardiac surgical patients, we investigated the association of circulating 25-hydroxyvitamin D (25OHD; indicator of nutritional vitamin D status) and 1,25-dihydroxyvitamin D (1,25[OH]2D; active vitamin D hormone) with nosocomicial infections.
Original paper ↗Read more →Combined Treatment with Omega-3 Fatty Acid and Cholecalciferol Increases 1,25-Dihydroxyvitamin D Levels by Modulating Dysregulation of Vitamin D Metabolism in 5/6 Nephrectomy Rats
The aim of this study was to determine whether omega-3 FA and cholecalciferol have effects on vitamin D metabolism related to CYP27B1 and 24-hydroxylase (CYP24) activities in the kidney and liver of 5/6 nephrectomy (Nx) rats.
Original paper ↗Read more →Effects of Vitamin D Supplementation on IGF-1 and Calcitriol: A Randomized-Controlled Trial
We aimed to investigate effects of vitamin D supplementation on IGF-1 (primary outcome) and calcitriol (1,25(OH)2D) concentrations (secondary outcome).
Original paper ↗Read more →Low 1,25-dihydroxyvitamin D levels are associated with severe COVID-19: an observational study in hospitalized patients
This study aimed to evaluate the association of serum 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels with clinical severity and mortality among hospitalized patients with moderate and severe COVID-19.
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels in Breast Cancer Risk in Mali: A Case-Control Study
The aim of the current study was to determine the association between metabolites circulating in the blood, 25(OH)D and 1,25(OH)2D, and vitamin D levels with the risk of breast cancer in Malian women.
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels in Breast Cancer Risk in Mali: A Case-Control Study
The aim of the current study was to determine the association between metabolites circulating in the blood, 25(OH)D and 1,25(OH)2D, and vitamin D levels with the risk of breast cancer in Malian women.
Original paper ↗Read more →Pregnancy-associated alterations in circulating vitamin D metabolites: higher total 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D without increased free 25-hydroxyvitamin D
Total 25-hydroxyvitamin D [25(OH)D], free 25-hydroxyvitamin D, and total 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations were compared between pregnant and nonpregnant women and across gestation using age-adjusted regression models.
Original paper ↗Read more →Rapid Nontranscriptional Effects of Calcifediol and Calcitriol
The purpose of this paper is to provide an overview of the rapid, non-genomic effects of calcifediol and calcitriol, whose elucidation could improve the understanding of the vitamin D3 endocrine system.
Original paper ↗Read more →Vitamin D Status among Thai School Children and the Association with 1,25-Dihydroxyvitamin D and Parathyroid Hormone Levels
Only 4% (21 of 529) participants had a serum 25(OH)D level below 50 nmol/L.
Original paper ↗Read more →Vitamin D Status and Indices of Mineral Homeostasis in the Population: Differences Between 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D
This population-based study investigated cross-sectionally the associations of 25-hydroxyvitamin D (calcidiol) and 1,25-dihydroxyvitamin D (calcitriol) with indices of mineral homeostasis.
Original paper ↗Read more →Why Normal 1,25-Dihydroxyvitamin D Does Not Rule Out Low Vitamin D Status
Learn why normal 1,25-dihydroxyvitamin D does not rule out low vitamin D status and how hormonal regulation can preserve active vitamin D levels.
Read more →Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab Bone Mineral Density Response: A Stratified Analysis by Renal Function Category and Prior Treatment History in a Real-World Japanese Cohort
This study investigated whether the renal function category and prior treatment history modified the association between baseline 25OHD and romosozumab BMD response.
Original paper ↗Read more →Context-Dependent Association Between Serum 25-Hydroxyvitamin D and Romosozumab Bone Mineral Density Response: A Stratified Analysis by Renal Function Category and Prior Treatment History in a Real-World Japanese Cohort
This study investigated whether the renal function category and prior treatment history modified the association between baseline 25OHD and romosozumab BMD response.
Original paper ↗Read more →Original sources
Promoting improved utilization of laboratory testing through changes in an electronic medical record: experience at an academic medical center
This case study over time describes five years of experience with interventions to improve laboratory test utilization at an academic medical center.
Publication details
Promoting improved utilization of laboratory testing through changes in an electronic medical record: experience at an academic medical center. Krasowski MD et al. BMC Medical Informatics and Decision Making. 2015;15:11.
Optimizing vitamin D naming conventions in computerized order entry to support high-value care
Published in White AA et al. Journal of the American Medical Informatics Association (2017).
Publication details
Optimizing vitamin D naming conventions in computerized order entry to support high-value care. White AA et al. Journal of the American Medical Informatics Association. 2017;24:172 to 175.
Vitamin D: marker, measurand & measurement
Published in Dirks NF, Cavalier E, Heijboer AC. Endocrine Connections (2023).
Publication details
Vitamin D: marker, measurand & measurement. Dirks NF, Cavalier E, Heijboer AC. Endocrine Connections. 2023;12:e220269.